GlassScriptPhysician profile
Vladlen Kim
NPI 1770557506
$32,489.45
in general payments reported to CMS, 2019-2025
44 companies · $7,453 in 2025
The $7,453 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $513 · 2021: $1,433 · 2022: $1,154 · 2023: $1,873 · 2024: $19K · 2025: $7,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $3,786 · Travel and Lodging: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,460.00 |
| Food and Beverage | $3,785.65 |
| Travel and Lodging | $356.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17,951.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $9,094.01 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,058.87 | 2019-2025 | |
| Pfizer INC. | $558.67 | 2019-2025 | |
| Amgen INC. | $545.64 | 2019-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $374.00 | 2019-2025 | Eliquis |
| Horizon Therapeutics Plc | $318.67 | 2019-2021 | |
| Esperion Therapeutics, INC. | $260.11 | 2021-2022 | |
| Novo Nordisk INC | $235.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $187.31 | 2020-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Axsome Therapeutics, INC. | $176.93 | 2025 | Symbravo, Auvelity |
| Lilly USA, LLC | $152.61 | 2019-2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.41 | 2020-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $138.25 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $132.22 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladlen Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.